Abbott Laboratories (ABT) has been in focus with announcements in the bio-tech space. The company's Libre Assist has expanded its digital diabetes offerings, integrating AI features. Analysts have raised price targets to as high as $169.00 and several brokerages maintain Buy recommendations for ABT. Returns over the last 5 years were stated to be 27% and the company has seen steady multi-year returns. Abbott announced a 7% dividend increase amidst global market uncertainties including tariffs and China-related headwinds. Their new Libre Assist AI tool and pediatric heart device clearances have potential implications for investors. However, the stock's recent performance and buy, sell or hold prospective after Q3 earnings are under debate. The implications of Abbott's acquisition of Exact Sciences are also under scrutiny. The corporation suffered from a Q3 topline miss and a guidance fall, causing the stock price to decline. However, the potential growth, dividend opportunity, and value still make ABT a watch-worthy stock in the bio-tech market. Investors are cautious about insider selling that has taken place and the mixed results from various segments.
Abbott Laboratories ABT News Analytics from Fri, 09 May 2025 07:00:00 GMT to Sat, 10 Jan 2026 21:02:00 GMT -
Rating 4
- Innovation 2
- Information 5
- Rumor -7
